Product Overview
Helios is a Dragon Pharma injectable blend built from two sympathomimetics rather than from an androgen: clenbuterol, a beta-2 adrenergic agonist better known as a bronchodilator, and yohimbine, an alpha-2 adrenergic antagonist. Both are carried in one oily solution for injection, supplied as a 10 ml vial. Neither component is a steroid, so the blend brings no aromatization, no estrogenic activity and no shutdown of the hypothalamic-pituitary-gonadal axis.
One formula, one job, two levers pulled at once. Clenbuterol drives thermogenesis and raises the rate at which the body burns energy, while yohimbine lifts the alpha-2 brake that holds stored fat where it is, so the pair covers both sides of the same outcome and neither agent alone reproduces the other. The clearance rates differ sharply and that shapes the schedule: clenbuterol is the long one, with sources giving 36-48 hours, a federal reference narrowing it to 25-39 hours and one recent review settling near 35, while yohimbine clears in 0.25-2.5 hours. The fat-loss literature around yohimbine uses roughly 0.2 mg per kilogram of body weight daily, and the mismatch is the practical detail - symptoms belonging to the slow side of the blend do not stop when the last injection is skipped, so the slow fade is part of planning. The same thermogenic family is also sold as a stronger three-compound version, CY3, and the tablet form of the same beta-2 agonist is available as Clenbuterol 40 mcg.
This product belongs to a cutting block, where the calorie deficit and the cardio do the work and the blend raises the energy expenditure side of the equation. It does not build muscle: the sources record that the anabolic effect claimed for clenbuterol in humans is not confirmed. It is also not a product for anyone with heart or blood pressure problems, which is why the dose ladder below moves in small steps and why pulse, blood pressure and potassium are the values that guide it.
Dosage Protocol
Doses are written daily, and the blend is run in blocks rather than continuously because beta-2 receptor adaptation develops in roughly two weeks. The ranges below follow the values recorded in the sources for this combination.
| Beginner | Clenbuterol 20-40 mcg daily with yohimbine 5-10 mg daily; 2 weeks on and 2 weeks off, titrating every 2-3 days by tolerance |
| Intermediate | Clenbuterol 40-80 mcg daily with yohimbine 10-15 mg daily across 2-3 blocks; split the clenbuterol into two doses and watch pulse and blood pressure |
| Advanced | Clenbuterol 80-120 mcg daily with yohimbine up to 0.2 mg per kg daily; 2-week blocks with no more than 6-8 weeks of total use |
| Female | Clenbuterol 20-40 mcg daily with yohimbine 5-10 mg daily in the same 2-week blocks, but the reference sources for this card carry no confirmed safe female protocol |
| Administration | Oral or intramuscular for the blend; blocks are used because beta-2 adaptation arrives in about two weeks, and no other stimulant belongs on top |
Suggested Protocols
Three ways this blend is used inside a cutting phase. Each combination names its partners as links to their product pages in the Dragon Pharma line.
What to Expect
- Heat and sweating. Raised body temperature and increased perspiration usually appear in the first days of a block.
- Stimulation and work capacity. Users report a stimulant effect from the first days, similar in feel to ephedrine.
- Weight loss. The drop comes mainly from a higher calorie expenditure, not from any muscle-building action.
- Limitation: no muscle. The anabolic effect claimed for clenbuterol in humans is not confirmed by the sources, so this is not a mass product.
- Tremor and heart rate. Shaking hands and a racing pulse are common and dose-dependent, especially when the starting dose is exceeded.
- Adaptation. By the close of week two the thermogenic response has already faded, which is why a break follows each block instead of the dose being pushed higher.
- Limitation: cardiac risk. With existing heart or blood pressure problems this combination is not safe, and the sources describe no way to make it so.
Side Effects and Management
Every effect below is tied to the stimulant load and moves with the dose, so the first response is always to reduce rather than to add anything.
Post-Cycle Therapy
This is a thermogenic blend, not an androgen, so there is no hormonal recovery to run afterwards and the sources list no SERM step. What actually ends a block is beta-2 receptor adaptation: the fat-loss response fades, and pressing on only adds stimulant load.
